Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
buparlisib + lomustine
- Development stage
- Discontinued
- Lead developer
- Adlai Nortye
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of buparlisib, a pan-phosphatidylinositol 3-kinase (PI3K) inhibitor, and lomustine, an alkylating agent. This combination was investigated for the treatment of recurrent glioblastoma multiforme (GBM) that had progressed after standard therapy with radiotherapy and temozolomide.
- Other names
- buparlisib + CCNU
02
Targets
DNAPIK3CA (Phosphoinositide 3-kinase alpha)PIK3CB (Phosphatidylinositol 3-kinase beta subunit)PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)PIK3CD (Phosphatidylinositol 3-kinase delta)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on buparlisib + lomustine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on buparlisib + lomustine.